This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
respiratory syndrome | 172 |
novel coronavirus | 137 |
public health | 136 |
acute respiratory | 110 |
syndrome coronavirus | 110 |
saudi arabia | 106 |
middle east | 105 |
east respiratory | 100 |
mass gatherings | 99 |
hajj pilgrims | 76 |
infectious disease | 75 |
infectious diseases | 74 |
severe acute | 73 |
coronavirus disease | 70 |
infect dis | 66 |
mass gathering | 64 |
cord uid | 63 |
travel med | 63 |
doc id | 63 |
dis doi | 63 |
med infect | 63 |
healthcare workers | 60 |
respiratory tract | 57 |
travel medicine | 54 |
respiratory infections | 53 |
world health | 51 |
health organization | 49 |
united states | 46 |
health care | 40 |
sore throat | 39 |
asymptomatic cases | 38 |
respiratory symptoms | 38 |
infection control | 38 |
influenza virus | 36 |
clinical trials | 35 |
pandemic influenza | 34 |
clinical symptoms | 34 |
cov infection | 33 |
respiratory viruses | 33 |
among pilgrims | 32 |
confirmed cases | 32 |
clinical characteristics | 31 |
coronavirus infection | 31 |
ebola virus | 31 |
risk factors | 30 |
virus infection | 30 |
tract infections | 29 |
control measures | 28 |
human transmission | 26 |
general population | 25 |
tb patients | 25 |
infected patients | 25 |
preventive measures | 24 |
hajj season | 24 |
systematic review | 24 |
fatality rate | 23 |
high risk | 23 |
tb management | 23 |
per day | 22 |
incidence rate | 22 |
social distancing | 22 |
hong kong | 22 |
hospitalized patients | 22 |
hospital admission | 22 |
sars coronavirus | 22 |
tested positive | 22 |
intensive care | 21 |
clinical features | 21 |
imported cases | 21 |
influenza vaccination | 20 |
influenza vaccine | 20 |
face masks | 20 |
reproduction number | 20 |
corona virus | 20 |
hajj pilgrimage | 19 |
viral load | 19 |
exposure prophylaxis | 19 |
upper respiratory | 19 |
symptomatic cases | 19 |
disease arrival | 19 |
early disease | 19 |
respiratory diseases | 18 |
virus disease | 18 |
iranian pilgrims | 18 |
previous studies | 18 |
contact tracing | 18 |
like illness | 18 |
influenza viruses | 18 |
respiratory pathogens | 17 |
current study | 17 |
control group | 17 |
antibody prophylaxis | 17 |
admission interval | 17 |
respiratory illness | 17 |
respiratory distress | 16 |
infections among | 16 |
body temperature | 16 |
elderly people | 16 |
tb cases | 16 |
case fatality | 16 |
influenza pandemic | 16 |
young people | 16 |
hand hygiene | 16 |
incubation period | 16 |
severe disease | 16 |
medical care | 16 |
years old | 16 |
health authorities | 16 |
disease control | 16 |
among hajj | 15 |
imported infectious | 15 |
suspected cases | 15 |
statistically significant | 15 |
study design | 15 |
emerging infectious | 15 |
zika virus | 15 |
human coronavirus | 15 |
global health | 15 |
study period | 14 |
travel health | 14 |
mechanical ventilation | 14 |
median age | 14 |
cohort study | 14 |
surveillance system | 14 |
tract infection | 14 |
hajj cough | 14 |
family cluster | 14 |
one health | 14 |
coronavirus pneumonia | 14 |
patients infected | 14 |
french pilgrims | 14 |
world cup | 14 |
infection among | 14 |
severe covid | 13 |
clinical course | 13 |
air travel | 13 |
disease surveillance | 13 |
ace receptor | 13 |
study showed | 13 |
pneumococcal vaccination | 13 |
mortality rate | 13 |
gansu province | 13 |
viral infections | 13 |
japanese travelers | 13 |
seasonal influenza | 13 |
coronavirus outbreak | 13 |
antiviral activity | 13 |
transmission dynamics | 13 |
health security | 13 |
severe cases | 13 |
sectional study | 13 |
index case | 13 |
situation report | 13 |
confirmed covid | 13 |
spike glycoprotein | 12 |
million people | 12 |
cov outbreak | 12 |
disease outbreaks | 12 |
respiratory infection | 12 |
data collection | 12 |
among travelers | 12 |
saharan africa | 12 |
descriptive study | 12 |
study sponsors | 12 |
observational study | 12 |
reproduction numbers | 12 |
among iranian | 12 |
receptor binding | 12 |
viral respiratory | 12 |
control strategies | 12 |
latin america | 11 |
confirmed tb | 11 |
increased risk | 11 |
basic reproduction | 11 |
viral shedding | 11 |
dengue fever | 11 |
malaria cases | 11 |
intermediate host | 11 |
patients admitted | 11 |
national health | 11 |
refugee camps | 11 |
virus replication | 11 |
sars outbreak | 11 |
communicable disease | 11 |
mean age | 11 |
health facilities | 11 |
large number | 11 |
spring festival | 11 |
outbreak control | 11 |
median early | 11 |
north america | 11 |
care unit | 11 |
default model | 10 |
virus infections | 10 |
new coronavirus | 10 |
diseases among | 10 |
new york | 10 |
gathering medicine | 10 |
symptoms onset | 10 |
care workers | 10 |
intermediate hosts | 10 |
age groups | 10 |
ill travelers | 10 |
secondary infections | 10 |
tb suspects | 10 |
authors declare | 10 |
metropolitan areas | 10 |
mers coronavirus | 10 |
least one | 10 |
pilgrims returning | 10 |
clinical trial | 10 |
pneumococcal vaccine | 10 |
cov infected | 10 |
useful videos | 10 |
symptomatic patients | 10 |
south korea | 10 |
international quarantine | 10 |
communicable diseases | 10 |
early stages | 10 |
close contact | 10 |
respiratory failure | 10 |
community acquired | 10 |
another study | 10 |
kidney injury | 9 |
severe pneumonia | 9 |
among healthcare | 9 |
patients presenting | 9 |
suspected tb | 9 |
dry cough | 9 |
respiratory disease | 9 |
spike protein | 9 |
emergency department | 9 |
epidemiological characteristics | 9 |
nan travel | 9 |
chest pain | 9 |
cell entry | 9 |
hospital transmission | 9 |
early detection | 9 |
international mass | 9 |
may also | 9 |
healthcare facilities | 9 |
health system | 9 |
conducted among | 9 |
travel rush | 9 |
travel restrictions | 9 |
among patients | 9 |
throat swabs | 9 |
tb diagnosis | 9 |
infected group | 9 |
malaria incidence | 9 |
secondary cases | 9 |
health measures | 9 |
subjective fever | 9 |
oxygen saturation | 9 |
cases may | 9 |
religious gatherings | 9 |
sexual assault | 9 |
symptomatically infectious | 9 |
potential conflicts | 9 |
health officials | 9 |
mers cases | 9 |
even though | 9 |
iranian hajj | 9 |
major concern | 9 |
controlled trial | 9 |
viral rna | 9 |
patient isolation | 9 |
ace receptors | 9 |
infected people | 9 |
coronavirus infections | 9 |
based study | 9 |
acquired pneumonia | 9 |
health interventions | 9 |
religious tourism | 9 |
common symptoms | 8 |
monoclonal antibodies | 8 |
outbreak size | 8 |
gastrointestinal symptoms | 8 |
acute kidney | 8 |
since onset | 8 |
health risks | 8 |
medical history | 8 |
disease outbreak | 8 |
bat origin | 8 |
north american | 8 |
disease journal | 8 |
nucleic acid | 8 |
highest number | 8 |
clinical signs | 8 |
health agencies | 8 |
incidence rates | 8 |
hajj seasons | 8 |
human coronaviruses | 8 |
confirmed case | 8 |
binding domain | 8 |
significantly lower | 8 |
based transmission | 8 |
high rate | 8 |
measures among | 8 |
first time | 8 |
serial interval | 8 |
rapid spread | 8 |
among malaysian | 8 |
com locate | 8 |
time since | 8 |
emerging respiratory | 8 |
vaccination status | 8 |
randomized clinical | 8 |
international students | 8 |
control study | 8 |
via air | 8 |
chinese spring | 8 |
logistic regression | 8 |
arabian peninsula | 8 |
rheumatoid arthritis | 8 |
age group | 8 |
malaria chemoprophylaxis | 8 |
sporting events | 8 |
significantly higher | 8 |
retrospective analysis | 8 |
home countries | 8 |
saudi pilgrims | 8 |
umrah pilgrims | 8 |
management guidelines | 8 |
hospital outbreak | 8 |
supplemental table | 8 |
chinese government | 8 |
cases reported | 8 |
global spread | 8 |
infected pneumonia | 8 |
person transmission | 8 |
cov cases | 8 |
confirmed mers | 8 |
many countries | 8 |
journal homepage | 8 |
pleural effusion | 8 |
viral infection | 8 |
interferon beta | 8 |
cov patients | 8 |
locate tmaid | 8 |
french hajj | 8 |
pilgrims attending | 8 |
ncov infection | 8 |
critically ill | 8 |
healthcare worker | 8 |
also reported | 8 |
new cases | 8 |
may help | 8 |
ill patients | 8 |
hubei province | 7 |
common among | 7 |
infection rate | 7 |
human stampedes | 7 |
international society | 7 |
sars epidemic | 7 |
syndromic surveillance | 7 |
million pilgrims | 7 |
healthcare providers | 7 |
denominator data | 7 |
care units | 7 |
international health | 7 |
travel history | 7 |
chain reaction | 7 |
hospitalized sars | 7 |
cases generated | 7 |
fifa world | 7 |
care facilities | 7 |
tested negative | 7 |
sars patients | 7 |
crowded conditions | 7 |
animal species | 7 |
common symptom | 7 |
care system | 7 |
two weeks | 7 |
cases per | 7 |
much higher | 7 |
human stampede | 7 |
transmission rate | 7 |
scout jamboree | 7 |
seir model | 7 |
patients diagnosed | 7 |
avian influenza | 7 |
common cold | 7 |
local public | 7 |
uk pilgrims | 7 |
south america | 7 |
health centers | 7 |
studies showed | 7 |
nasal carriage | 7 |
medical fees | 7 |
tertiary care | 7 |
healthcare system | 7 |
viruses among | 7 |
septic shock | 7 |
malaysian pilgrims | 7 |
attack rate | 7 |
emergency room | 7 |
emerging coronavirus | 7 |
misleading videos | 7 |
time reverse | 7 |
papua new | 7 |
polymerase chain | 7 |
one study | 7 |
chronic diseases | 7 |
diagnostic test | 7 |
primary care | 7 |
arrival time | 7 |
early treatment | 7 |
distress syndrome | 7 |
active tb | 7 |
informed consent | 7 |
chronic disease | 7 |
ct scan | 7 |
cytokine storm | 7 |
rhinovirus infections | 7 |
novel influenza | 7 |
zoonotic spillover | 7 |
face mask | 7 |
first case | 7 |
arrival times | 7 |
primary health | 7 |
health response | 7 |
new guinea | 7 |
case study | 7 |
global population | 6 |
natural host | 6 |
pernambuco state | 6 |
nipah virus | 6 |
familial cluster | 6 |
respiratory syncytial | 6 |
first cases | 6 |
systemic lupus | 6 |
well known | 6 |
human behavior | 6 |
therapeutic efficacy | 6 |
adverse effects | 6 |
critical illness | 6 |
dromedary camels | 6 |
medical records | 6 |
muslim pilgrimage | 6 |
sars virus | 6 |
patients treated | 6 |
travelers returning | 6 |
next day | 6 |
entry interventions | 6 |
early outpatient | 6 |
dear editor | 6 |
pulmonary disease | 6 |
second wave | 6 |
antiviral effects | 6 |
international airport | 6 |
including influenza | 6 |
ncov epidemic | 6 |
presenting symptoms | 6 |
may lead | 6 |
review board | 6 |
respiratory virus | 6 |
mortality rates | 6 |
countries affected | 6 |
northeast brazil | 6 |
observed among | 6 |
human immunodeficiency | 6 |
species jumping | 6 |
epidemic peak | 6 |
health services | 6 |
health emergency | 6 |
african countries | 6 |
across studies | 6 |
year period | 6 |
pharmaceutical interventions | 6 |
pregnant patients | 6 |
total number | 6 |
quarantine procedures | 6 |
screening tests | 6 |
clinical manifestations | 6 |
saudi ministry | 6 |
competing interests | 6 |
genome sequence | 6 |
host range | 6 |
international spread | 6 |
paratyphoid fever | 6 |
world regions | 6 |
expected number | 6 |
mtb rif | 6 |
different countries | 6 |
less likely | 6 |
influenza positive | 6 |
positive cases | 6 |
coronavirus indicating | 6 |
sample size | 6 |
clinical data | 6 |
high proportion | 6 |
pregnant women | 6 |
within days | 6 |
respiratory viral | 6 |
health approach | 6 |
susceptible population | 6 |
gathering events | 6 |
infectious people | 6 |
species barrier | 6 |
fourteen days | 6 |
first two | 6 |
initial cases | 6 |
cov among | 6 |
healthcare associated | 6 |
emergency rooms | 6 |
high rates | 6 |
interval reduction | 6 |
immunodeficiency virus | 6 |
glass opacities | 6 |
target cells | 6 |
per liter | 6 |
treated patients | 6 |
general hospital | 6 |
central nervous | 6 |
chronic conditions | 6 |
older adults | 6 |
small sample | 6 |
syncytial virus | 6 |
international concern | 6 |
patients tested | 6 |
annual hajj | 6 |
mg kg | 6 |
world scout | 6 |
affected countries | 6 |
average age | 6 |
isolation procedures | 6 |
among elderly | 6 |
retrospective cohort | 6 |
mild cases | 6 |
southern hemisphere | 6 |
among returning | 6 |
disease spread | 6 |
contact rate | 6 |
organ failure | 6 |
european union | 6 |
lupus erythematosus | 6 |
reported among | 5 |
tb risk | 5 |
central america | 5 |
professional judgement | 5 |
gathering event | 5 |
ii clinical | 5 |
southeast asia | 5 |
imaging findings | 5 |
randomized controlled | 5 |
small study | 5 |
included studies | 5 |
antiviral drugs | 5 |
united kingdom | 5 |
secondary interest | 5 |
epidemic model | 5 |
mildly symptomatic | 5 |
feline infectious | 5 |
rate reduction | 5 |
phase ii | 5 |
interest exists | 5 |
atypical pneumonia | 5 |
infection prevention | 5 |
therapeutic option | 5 |
bronchitis virus | 5 |
suspected patients | 5 |
diagnostic tests | 5 |
judgement concerning | 5 |
expert testimony | 5 |
applications registrations | 5 |
reverse transmission | 5 |
epidemic curves | 5 |
international metropolitan | 5 |
young adults | 5 |
old man | 5 |
academic institutions | 5 |
protective equipment | 5 |
old woman | 5 |
species barriers | 5 |
like sars | 5 |
highly contagious | 5 |
avian infectious | 5 |
cross sectional | 5 |
temperature screening | 5 |
vitro antiviral | 5 |
clinical findings | 5 |
displaced people | 5 |
adverse events | 5 |
include employment | 5 |
cough etiquette | 5 |
study population | 5 |
per square | 5 |
travel care | 5 |
video sharing | 5 |
every two | 5 |
higher risk | 5 |
mandarin videos | 5 |
novel corona | 5 |
institutional review | 5 |
virus types | 5 |
clinical description | 5 |
case control | 5 |
may require | 5 |
outpatient treatment | 5 |
asymptomatic infection | 5 |
low risk | 5 |
financial gain | 5 |
holy sites | 5 |
like symptoms | 5 |
stock ownership | 5 |
personal rivalry | 5 |
wear masks | 5 |
much lower | 5 |
masks may | 5 |
discern score | 5 |
admitted patients | 5 |
returning travelers | 5 |
case definition | 5 |
hemorrhagic fever | 5 |
largest mass | 5 |
may influence | 5 |
hcq az | 5 |
household income | 5 |
days since | 5 |
million face | 5 |
case importation | 5 |
developing countries | 5 |
northern hemisphere | 5 |
reported symptoms | 5 |
adult inpatients | 5 |
among umrah | 5 |
possible therapeutic | 5 |
minimum wages | 5 |
social isolation | 5 |
financial interest | 5 |
risk assessment | 5 |
immune response | 5 |
johns hopkins | 5 |
two years | 5 |
sporting event | 5 |
converting enzyme | 5 |
also shown | 5 |
influenza season | 5 |
patients hospitalized | 5 |
alt values | 5 |
coronavirus spike | 5 |
primary interest | 5 |
per population | 5 |
wide range | 5 |
streptococcus pneumoniae | 5 |
tuberculosis infection | 5 |
international travel | 5 |
three times | 5 |
intravenous infusion | 5 |
spillover events | 5 |
healthcare settings | 5 |
affected areas | 5 |
publicly reported | 5 |
rate among | 5 |
recent study | 5 |
patients died | 5 |
south africa | 5 |
viral diseases | 5 |
security agenda | 5 |
among french | 5 |
xpert mtb | 5 |
species transmission | 5 |
personal protective | 5 |
confined area | 5 |
nervous system | 5 |
surveillance data | 5 |
vaccine strains | 5 |
presumptive place | 5 |
may arise | 5 |
news agencies | 5 |
participants reported | 5 |
armed conflict | 5 |
infected individuals | 5 |
ethics committee | 5 |
infectious peritonitis | 5 |
virus transmission | 5 |
higher number | 5 |
paid expert | 5 |
test result | 5 |
interest include | 5 |
large numbers | 5 |
family contacts | 5 |
indicating person | 5 |
pneumonia associated | 5 |
asymptomatic individuals | 5 |
geosentinel sites | 5 |
among others | 5 |
pulmonary inflammation | 5 |
runny nose | 5 |
severe dyspnea | 5 |
previously reported | 5 |
common respiratory | 5 |
exposed people | 5 |
imported case | 5 |
response planning | 5 |
infectious bronchitis | 5 |
hajj planners | 5 |
th century | 5 |
patent applications | 5 |
protease tmprss | 5 |
malaysian hajj | 5 |
policy makers | 5 |
health departments | 5 |
tb drugs | 5 |
pulmonary tuberculosis | 5 |
conflicting interest | 5 |
running nose | 5 |
reported cases | 5 |
two cases | 5 |
mitigation strategies | 5 |
antimalarial drugs | 5 |
influenza infection | 5 |
disease xxx | 5 |
chest ct | 5 |
first report | 4 |
large enough | 4 |
immune responses | 4 |
global public | 4 |
susceptible persons | 4 |
recently emerged | 4 |
respiratory rate | 4 |
kappa coefficient | 4 |
ebola outbreak | 4 |
government agencies | 4 |
multicenter study | 4 |
demographic characteristics | 4 |
human population | 4 |
homeland security | 4 |
seafood market | 4 |
asymptomatically infectious | 4 |
positive sars | 4 |
tb guidelines | 4 |
effectively inhibit | 4 |
among australian | 4 |
baseline value | 4 |
patients aged | 4 |
potential effects | 4 |
disease requires | 4 |
king abdul | 4 |
viral nucleic | 4 |
imaging features | 4 |
infected person | 4 |
chloroquine effectively | 4 |
first covid | 4 |
returning pilgrims | 4 |
festival travel | 4 |
years ago | 4 |
exposed persons | 4 |
cohort studies | 4 |
patient care | 4 |
positive rt | 4 |
vitro inhibition | 4 |
sputum culture | 4 |
sars outbreaks | 4 |
may prove | 4 |
west africa | 4 |
factors associated | 4 |
tb infection | 4 |
whole genome | 4 |
optimized dosing | 4 |
current situation | 4 |
good safety | 4 |
many studies | 4 |
serum samples | 4 |
high number | 4 |
new year | 4 |
medical information | 4 |
international airports | 4 |
muslim population | 4 |
vaccination guidelines | 4 |
recipient countries | 4 |
animal models | 4 |
study provides | 4 |
treating covid | 4 |
tb incidence | 4 |
influenza vaccines | 4 |
four times | 4 |
case reports | 4 |
reservoir host | 4 |
china clinical | 4 |
studies reported | 4 |
assess risk | 4 |
severe illness | 4 |
icu admission | 4 |
future studies | 4 |
religious pilgrims | 4 |
entry screening | 4 |
serine protease | 4 |
malarial drugs | 4 |
epidemic models | 4 |
may play | 4 |
australian perspective | 4 |
alcohol hand | 4 |
wuhan city | 4 |
also presented | 4 |
including deaths | 4 |
highest rate | 4 |
reported confirmed | 4 |
th percentile | 4 |
including hcws | 4 |
previous findings | 4 |
constant infectivity | 4 |
hajj may | 4 |
clinical practice | 4 |
combination lopinavir | 4 |
reverse transcriptase | 4 |
coronavirus sars | 4 |
boa viagem | 4 |
guideline compliance | 4 |
nucleic acids | 4 |
ksa tb | 4 |
among visitors | 4 |
see table | 4 |
viral pathogens | 4 |
categorical variables | 4 |
care centers | 4 |
serological study | 4 |
useful information | 4 |
related coronavirus | 4 |
case report | 4 |
respiratory samples | 4 |
specific antiviral | 4 |
mononuclear cells | 4 |
respiratory symptom | 4 |
zoonotic links | 4 |
prophylaxis targeted | 4 |
rvp fast | 4 |
publicly available | 4 |
misleading information | 4 |
rna polymerase | 4 |
growth rate | 4 |
median time | 4 |
chemoprophylaxis use | 4 |
ocular toxicity | 4 |
diabetes mellitus | 4 |
may increase | 4 |
hemisphere influenza | 4 |
took antibiotics | 4 |
rapid detection | 4 |
developed fever | 4 |
great concern | 4 |
aged less | 4 |
cause severe | 4 |
positive test | 4 |
hajj influenza | 4 |
population structure | 4 |
transmitted infection | 4 |
information available | 4 |
asymptomatic sars | 4 |
dosing design | 4 |
escherichia coli | 4 |
travel consultation | 4 |
lactate dehydrogenase | 4 |
computed tomography | 4 |
th day | 4 |
human interface | 4 |
returning hajj | 4 |
tb transmission | 4 |
identifying tb | 4 |
domestic hajjis | 4 |
treatment options | 4 |
olympic games | 4 |
laboratory tests | 4 |
taste disorders | 4 |
one imported | 4 |
abdul aziz | 4 |
contacts among | 4 |
rights reserved | 4 |
prospective cohort | 4 |
emerging coronaviruses | 4 |
youth day | 4 |
case series | 4 |
significantly reduced | 4 |
missing data | 4 |
early diagnosis | 4 |
mathematical model | 4 |
emerged novel | 4 |
largest number | 4 |
household contacts | 4 |
individual countries | 4 |
tb control | 4 |
hajj attendees | 4 |
vertical transmission | 4 |
including million | 4 |
natural hosts | 4 |
wuhan virus | 4 |
among young | 4 |
early recognition | 4 |
independent users | 4 |
illness among | 4 |
religious mass | 4 |
patients clinical | 4 |
infectious person | 4 |
modelling study | 4 |
higher viral | 4 |
virus tropism | 4 |
initial description | 4 |
mitigation measures | 4 |
kayseri city | 4 |
international tb | 4 |
million attendees | 4 |
frequently reported | 4 |
associated viral | 4 |
survival rate | 4 |
cell count | 4 |
diagnosing tb | 4 |
main reason | 4 |
flight data | 4 |
medical sciences | 4 |
oluwatomi iken | 4 |
saudi arabian | 4 |
swine flu | 4 |
novel communicable | 4 |
hospitalization risk | 4 |
first confirmed | 4 |
day admission | 4 |
among domestic | 4 |
also showed | 4 |
bat sars | 4 |
global surveillance | 4 |
high prevalence | 4 |
clinical samples | 4 |
grade fever | 4 |
mg attendance | 4 |
without sputum | 4 |
novel infectious | 4 |
medication use | 4 |
internal medicine | 4 |
human monoclonal | 4 |
state council | 4 |
since infection | 4 |
hand sanitizer | 4 |
aspartate aminotransferase | 4 |
binding affinity | 4 |
throat pain | 4 |
tropical medicine | 4 |
current outbreak | 4 |
sputum samples | 4 |
clinical presentation | 4 |
world youth | 4 |
suspected mers | 4 |
viral dynamics | 4 |
sexual assaults | 4 |
early phase | 4 |
treated pilgrims | 4 |
vaccination coverage | 4 |
hajj mass | 4 |
st century | 4 |
adverse reactions | 4 |
public gatherings | 4 |
city hospital | 4 |
present study | 4 |
spatial distribution | 4 |
rna viruses | 4 |
high income | 4 |
square test | 4 |
virus type | 4 |
mobile phones | 4 |
coryzal symptoms | 4 |
treatment outcomes | 4 |
asian countries | 4 |
early stage | 4 |
health commission | 4 |
chikungunya virus | 4 |
latin american | 4 |
mathematical modelling | 4 |
western travelers | 4 |
alanine aminotransferase | 4 |
study reported | 4 |
consecutive patients | 4 |
spread rapidly | 4 |
constitutional symptoms | 4 |
infected returnees | 4 |
almost million | 4 |
three days | 4 |
malarial infections | 4 |
disease introduction | 4 |
low incidence | 4 |
antiviral remdesivir | 4 |
mild disease | 4 |
hajj questionnaire | 4 |
local symptoms | 4 |
risk groups | 4 |
new insights | 4 |
got sick | 4 |
authors contributed | 4 |
saudi hospitals | 4 |
clinical outcomes | 4 |
clinical cases | 4 |
long term | 4 |
summer olympics | 4 |
provide support | 4 |
analysis showed | 4 |
five days | 4 |
odds ratios | 4 |
health information | 4 |
gov travel | 4 |
medical staff | 4 |
typhoid fever | 4 |
analysis based | 4 |
mers cov | 4 |
symptom onset | 4 |
high tb | 4 |
tb suspected | 4 |
international air | 4 |
european countries | 4 |
madding crowd | 4 |
health impact | 4 |
short period | 4 |
normal range | 4 |
lopinavir ritonavir | 4 |
highly mobile | 4 |
one patient | 4 |
yellow fever | 4 |
main symptoms | 4 |
times higher | 4 |
conflicting interests | 4 |
cell surface | 4 |
comprehensive review | 4 |
various countries | 4 |
healthcare setting | 4 |
will change | 4 |
clinical presentations | 4 |
information regarding | 4 |
lower risk | 4 |
asymptomatic contact | 4 |
endemic areas | 4 |
authors sign | 4 |
guangdong province | 4 |
group patients | 4 |
population data | 4 |
united nations | 4 |
case definitions | 4 |
potential risks | 4 |
compassionate use | 4 |
attack rates | 4 |
kidney disease | 4 |
pneumonia outbreak | 4 |
age years | 4 |
chinese citizens | 4 |
severe patients | 4 |
elsevier ltd | 4 |
collected data | 4 |
hajj medical | 4 |
surveillance center | 4 |
risk scenario | 4 |
acute febrile | 4 |
disease reached | 4 |
every year | 4 |
side effects | 4 |
protective measures | 4 |
transmission routes | 4 |
outbreak among | 4 |
adaptive immune | 4 |
influenza like | 4 |
economic impact | 4 |
wild animals | 4 |
invasive mechanical | 4 |
average number | 4 |
mink farms | 3 |
potential outbreaks | 3 |
cumulative confirmed | 3 |
prevention methods | 3 |
multiple viruses | 3 |
included patients | 3 |
preventing infection | 3 |
pcr testing | 3 |
people infected | 3 |
symptomatic treatment | 3 |
provide information | 3 |
structural proteins | 3 |
supplementary data | 3 |
symptoms used | 3 |
malaria risk | 3 |
epithelial cells | 3 |
traveler screening | 3 |
virus shedding | 3 |
new zealand | 3 |
travel risk | 3 |
covid participants | 3 |
clinical condition | 3 |
japan national | 3 |
also found | 3 |
high medical | 3 |
untranslated region | 3 |
low levels | 3 |
six months | 3 |
influenza pandemics | 3 |
coronavirus epidemic | 3 |
american network | 3 |
studies need | 3 |
complete picture | 3 |
involved healthcare | 3 |
patients received | 3 |
epidemic progression | 3 |
potent inhibitor | 3 |
superspreader potential | 3 |
complete genome | 3 |
great potential | 3 |
new england | 3 |
infection including | 3 |
retrospective investigation | 3 |
related information | 3 |
epidemic reaches | 3 |
within china | 3 |
study evaluated | 3 |
cases worldwide | 3 |
previous research | 3 |
medical services | 3 |
common viral | 3 |
coronavirus pandemic | 3 |
will occur | 3 |
saudi residents | 3 |
prototypical novel | 3 |
one year | 3 |
significant difference | 3 |
six patients | 3 |
near east | 3 |
till march | 3 |
outbound travelers | 3 |
elevated levels | 3 |
among people | 3 |
border care | 3 |
hajj sites | 3 |
returning home | 3 |
health surveillance | 3 |
study conducted | 3 |
future outbreaks | 3 |
tourist organization | 3 |
respiratory specimens | 3 |
egyptian pilgrims | 3 |
adult patients | 3 |
dotted line | 3 |
much less | 3 |
first consecutive | 3 |
i felt | 3 |
cov including | 3 |
comparability across | 3 |
per million | 3 |
patients showed | 3 |
use among | 3 |
one large | 3 |
large hmo | 3 |
social gatherings | 3 |
hospital transmissions | 3 |
england journal | 3 |
asymptomatic patients | 3 |
global outbreaks | 3 |
vaccine effectiveness | 3 |
epidemic prevention | 3 |
confidence interval | 3 |
risk factor | 3 |
severe novel | 3 |
religious pilgrimage | 3 |
domestic cases | 3 |
collection procedures | 3 |
open reading | 3 |
supplemental document | 3 |
aviation points | 3 |
worth noting | 3 |
travel consultations | 3 |
time rt | 3 |
control practices | 3 |
antiviral medications | 3 |
zoonotic coronaviruses | 3 |
pharmaceutical preventive | 3 |
available information | 3 |
ill pilgrims | 3 |
vivo studies | 3 |
moraxella catarrhalis | 3 |
nasal congestion | 3 |
infections follows | 3 |
especially respiratory | 3 |
cohorts ensure | 3 |
took place | 3 |
human metapneumovirus | 3 |
control law | 3 |
global economy | 3 |
pathogenic coronaviruses | 3 |
affiliated hospital | 3 |
nonpharmaceutical interventions | 3 |
line anti | 3 |
patients older | 3 |
also recommended | 3 |
large cohort | 3 |
either personally | 3 |
study also | 3 |
travellers returning | 3 |
median vs | 3 |
novel coronaviruses | 3 |
saudi health | 3 |
significant effect | 3 |
cdc definition | 3 |
male sex | 3 |
cov epidemic | 3 |
transmission among | 3 |
requiring hospitalisation | 3 |
pilgrims viral | 3 |
chronic obstructive | 3 |
close proximity | 3 |
disease states | 3 |
acquiring respiratory | 3 |
laboratory findings | 3 |
emerging disease | 3 |
million muslims | 3 |
countries worldwide | 3 |
studies provide | 3 |
infect humans | 3 |
foreign countries | 3 |
exposure history | 3 |
deceased patients | 3 |
high incidence | 3 |
pneumonia causing | 3 |
outpatient use | 3 |
health related | 3 |
heat map | 3 |
study group | 3 |
fatality rates | 3 |
acquired immunodeficiency | 3 |
cohort survey | 3 |
among japanese | 3 |
infectious agents | 3 |
infections due | 3 |
horseshoe bats | 3 |
malaria prevention | 3 |
febrile respiratory | 3 |
affected patients | 3 |
least two | 3 |
american pre | 3 |
supplement material | 3 |
mask use | 3 |
compliance score | 3 |
one third | 3 |
transmission potential | 3 |
air passengers | 3 |
origins resulted | 3 |
provide complementary | 3 |
pneumonia cases | 3 |
sars transmission | 3 |
conjugate vaccine | 3 |
etiologic agent | 3 |
spectrum antiviral | 3 |
statistical significance | 3 |
surveillance study | 3 |
pulmonary fibrosis | 3 |
hopkins coronavirus | 3 |
pakistani pilgrims | 3 |
parainfluenza viruses | 3 |
among hajjis | 3 |
containment measures | 3 |
search term | 3 |
two days | 3 |
burden countries | 3 |
mass religious | 3 |
total population | 3 |
patchy opacities | 3 |
iii clinical | 3 |
compliance scores | 3 |
clinical respiratory | 3 |
clinical diagnosis | 3 |
hospitalized adult | 3 |
predicted based | 3 |
health conditions | 3 |
last years | 3 |
infection rates | 3 |
clinical evidence | 3 |
prospective study | 3 |
twentieth century | 3 |
facilitate reporting | 3 |
global travel | 3 |
care personnel | 3 |
several limitations | 3 |
multinational follow | 3 |
countries around | 3 |
mild symptoms | 3 |
tahrir square | 3 |
multivariable model | 3 |
health community | 3 |
clinical treatment | 3 |
relatively short | 3 |
monoclonal antibody | 3 |
retrospective case | 3 |
complementary data | 3 |
social media | 3 |
reported case | 3 |
virus research | 3 |
relatively low | 3 |
potential among | 3 |
treating tb | 3 |
subpleural ground | 3 |
mg qd | 3 |
among mers | 3 |
acquired infection | 3 |
prevalence rates | 3 |
laboratory confirmation | 3 |
simulation tool | 3 |
sick enough | 3 |
phase iii | 3 |
pilgrims admitted | 3 |
metropolitan population | 3 |
among hospitalized | 3 |
four st | 3 |
treat covid | 3 |
like coronavirus | 3 |
based studies | 3 |
th cell | 3 |
high mortality | 3 |
international travelers | 3 |
resources efficiently | 3 |
prospective descriptive | 3 |
mycobacterium tuberculosis | 3 |
several countries | 3 |
better characterize | 3 |
international pilgrims | 3 |
infection risks | 3 |
monkey model | 3 |
four year | 3 |
travelers visiting | 3 |
temporal patterns | 3 |
associated illness | 3 |
host cells | 3 |
patients suffering | 3 |
patient safety | 3 |
defined according | 3 |
analysis presented | 3 |
spread globally | 3 |
population density | 3 |
close contacts | 3 |
care services | 3 |
national authorities | 3 |
university students | 3 |
tests per | 3 |
remdesivir solution | 3 |
antiviral strategies | 3 |
lymphocyte counts | 3 |
also likely | 3 |
older people | 3 |
pilot observational | 3 |
economic loss | 3 |
just prior | 3 |
published data | 3 |
developed countries | 3 |
modeling studies | 3 |
leading cause | 3 |
require hospitalization | 3 |
mina primary | 3 |
infectious period | 3 |
infection period | 3 |
fight covid | 3 |
retrospective cross | 3 |
two groups | 3 |
formal education | 3 |
possible transmission | 3 |
mina health | 3 |
health issues | 3 |
data interpretation | 3 |
reduced risk | 3 |
screening procedures | 3 |
retinal toxicity | 3 |
consistently used | 3 |
immune activation | 3 |
several studies | 3 |
continuous variables | 3 |
islamic belief | 3 |
largest annual | 3 |
global airline | 3 |
unknown whether | 3 |
significant differences | 3 |
christian pilgrimage | 3 |
travelers attending | 3 |
first videos | 3 |
food safety | 3 |
spread around | 3 |
spike gene | 3 |
responses based | 3 |
clinical management | 3 |
influenza patients | 3 |
high quality | 3 |
screening diagnostic | 3 |
host receptor | 3 |
two million | 3 |
medical problems | 3 |
travel implications | 3 |
pneumococcal disease | 3 |
antiviral effect | 3 |
large cluster | 3 |
label non | 3 |
precisely defined | 3 |
oral administration | 3 |
health ministry | 3 |
human airway | 3 |
infectious agent | 3 |
probable covid | 3 |
related deaths | 3 |
control sars | 3 |
hajj crowds | 3 |
included demographic | 3 |
time pcr | 3 |
studies among | 3 |
asymptomatic subjects | 3 |
attending patients | 3 |
renal disease | 3 |
recent research | 3 |
hyaline membrane | 3 |
study influenza | 3 |
infectious passengers | 3 |
neutrophil counts | 3 |
receptor ace | 3 |
treatment plan | 3 |
clinical experience | 3 |
pleural thickening | 3 |
kumbh mela | 3 |
pandemic strain | 3 |
geosentinel site | 3 |
geosentinel cross | 3 |
highest risk | 3 |
hajj period | 3 |
masks per | 3 |
study clinical | 3 |
large multinational | 3 |
blood count | 3 |
described previously | 3 |
reported data | 3 |
large population | 3 |
survivor patients | 3 |
current smokers | 3 |
ili symptoms | 3 |
comparative study | 3 |
seat counts | 3 |
fever plus | 3 |
foreign country | 3 |
atypical presentations | 3 |
two patients | 3 |
attributable events | 3 |
mean incidence | 3 |
achieve comparability | 3 |
nasopharyngeal swabs | 3 |
host ace | 3 |
wearing face | 3 |
crowd density | 3 |
effective response | 3 |
abdominal pain | 3 |
haemophilus parainfluenzae | 3 |
one respiratory | 3 |
mg attendees | 3 |
turkish citizens | 3 |
enterohemorrhagic escherichia | 3 |
attended umrah | 3 |
throat clinic | 3 |
forcibly displaced | 3 |
za zhi | 3 |
rates among | 3 |
achieve ro | 3 |
hepatic failure | 3 |
pcr test | 3 |
greater risk | 3 |
previous outbreaks | 3 |
epidemic threat | 3 |
scipv also | 3 |
ray findings | 3 |
high levels | 3 |
coronavirus covid | 3 |
crowded settings | 3 |
aviation medicine | 3 |
total patients | 3 |
cases appeared | 3 |
retrospective study | 3 |
clinical studies | 3 |
host cell | 3 |
novel viruses | 3 |
modified discern | 3 |
provides greater | 3 |
returning travellers | 3 |
times greater | 3 |
production capacity | 3 |
emergency services | 3 |
data obtained | 3 |
cov transmission | 3 |
heart disease | 3 |
cases involved | 3 |
recombination event | 3 |
vaccine preventable | 3 |
coronavirus outbreaks | 3 |
emerging novel | 3 |
antiviral agent | 3 |
ground glass | 3 |
disease transmission | 3 |
health recommendations | 3 |
renal damage | 3 |
another epidemic | 3 |
infectious persons | 3 |
severe respiratory | 3 |
matched cohorts | 3 |
ventricular arrhythmias | 3 |
square meter | 3 |
japanese surveillance | 3 |
health hazards | 3 |
disease severity | 3 |
obstructive pulmonary | 3 |
human bocavirus | 3 |
various medications | 3 |
target population | 3 |
passive immunization | 3 |
cumulative probability | 3 |
cov referral | 3 |
cov patient | 3 |
microbiological surveillance | 3 |
one another | 3 |
cardiovascular disease | 3 |
almost half | 3 |
greater opportunity | 3 |
board aircraft | 3 |
bilateral patchy | 3 |
many people | 3 |
susceptible people | 3 |
spreading infectious | 3 |
underlying risk | 3 |
current covid | 3 |
transmission occurs | 3 |
modified susceptible | 3 |
rna virus | 3 |
data show | 3 |
prednisone use | 3 |
australian hajj | 3 |
based syndromic | 3 |
young children | 3 |
human subjects | 3 |
regional laboratory | 3 |
crowd densities | 3 |
will continue | 3 |
survey conducted | 3 |
rhesus monkeys | 3 |
low fatality | 3 |
novel human | 3 |
imported disease | 3 |
arterial blood | 3 |
associated outbreak | 3 |
dramatic increase | 3 |
negative patients | 3 |
different covs | 3 |
working group | 3 |
infected individual | 3 |
lessons learned | 3 |
new use | 3 |
severely ill | 3 |
cytopathic effect | 3 |
participants reporting | 3 |
glass opacity | 3 |
mild respiratory | 3 |
taking medications | 3 |
influenza among | 3 |
immunocompromised patients | 3 |
initial stage | 3 |
prove crucial | 3 |
maternity hospital | 3 |
therefore necessary | 3 |
prophylaxis may | 3 |
fatality ratio | 3 |
define respiratory | 3 |
symptomatic transmission | 3 |
recent studies | 3 |
respiratory disorders | 3 |
advisory committee | 3 |
british study | 3 |
ensure better | 3 |
recent recombination | 3 |
illnesses among | 3 |
measures will | 3 |
emerging viral | 3 |
youtube videos | 3 |
patients reported | 3 |
flu vaccine | 3 |
large gatherings | 3 |
viral replication | 3 |
hospital admissions | 3 |
causing critical | 3 |
national tourist | 3 |
real time | 3 |
diagnoses among | 3 |
health problems | 3 |
developing vaccines | 3 |
holy land | 3 |
overseas chinese | 3 |
groups may | 3 |
ongoing covid | 3 |
mammalian hosts | 3 |
may th | 3 |
interim guidance | 3 |
study focused | 3 |
epidemiological data | 3 |
city pairs | 3 |
inhibitory effects | 3 |
human respiratory | 3 |
global community | 3 |
varied widely | 3 |
peripheral blood | 3 |
million masks | 3 |
systematic screening | 3 |
hcq alone | 3 |
early transmission | 3 |
starting april | 3 |
old male | 3 |
people per | 3 |
available data | 3 |
ncov outbreak | 3 |
younger age | 3 |
potential intermediate | 3 |
probable cases | 3 |
see supplemental | 3 |
unknown mysterious | 3 |
leverage resources | 3 |
full text | 3 |
productive cough | 3 |
routine surveillance | 3 |
also included | 3 |
i acquired | 3 |
nasopharyngeal swab | 3 |
new emerging | 3 |
chinese authorities | 3 |
samples tested | 3 |
animal origin | 3 |
cardiovascular diseases | 3 |
palm civet | 3 |
relevant papers | 3 |
modified seir | 3 |
solomon islands | 3 |
targeted antibody | 3 |
respiratory infectious | 3 |
people aged | 3 |
viral pneumonia | 3 |
rhinovirus infection | 3 |
plan responses | 3 |
case every | 3 |
among different | 3 |
people alone | 3 |
also examined | 3 |
might also | 3 |
autoimmune disease | 3 |
antibody cocktail | 3 |
bat coronavirus | 3 |
bat sarsr | 3 |
capacity building | 3 |
electronic dance | 3 |
cov replication | 3 |
since december | 3 |
tb burden | 3 |
medical expenses | 3 |
susceptible tb | 3 |
global alert | 3 |
inclusion criteria | 3 |
less toxic | 3 |
including sars | 3 |
reactive protein | 3 |
september th | 3 |
pneumococcal infections | 3 |
large proportion | 3 |
syrian refugee | 3 |
hydroxychloroquine sulfate | 3 |
referral hospital | 3 |
cumulative incidence | 3 |
poisson distribution | 3 |
significant morbidity | 3 |
showed bilateral | 3 |
measured fever | 3 |
patients may | 3 |
pandemic potential | 3 |
worldwide spread | 3 |
disease therapeutics | 3 |
among international | 3 |
tb screening | 3 |
disease progression | 3 |
airline transportation | 3 |
mainland china | 3 |
first days | 3 |
ten centuries | 3 |
literature review | 3 |
black nazarene | 3 |
th quarters | 3 |
imported diseases | 3 |
different parts | 3 |
tehran university | 3 |
population heterogeneity | 3 |
herpes simplex | 3 |
tb treatment | 3 |
qt prolongation | 3 |
coronavirus oc | 3 |
significant proportion | 3 |
infected mice | 3 |
accurately assess | 3 |
national institute | 3 |
one point | 3 |
care hospital | 3 |
first week | 3 |
clinical sites | 3 |
higher among | 3 |
pcr kit | 3 |
ncov remdesivir | 3 |
planned mass | 3 |
multiple organ | 3 |
epidemic potential | 3 |
blood pressure | 3 |
saudi patients | 3 |
like virus | 3 |
sierra leone | 3 |
endemic countries | 3 |
better comparability | 3 |
early reports | 3 |
aid public | 3 |
slightly higher | 3 |
primary cases | 3 |
health data | 3 |
sentinel reporting | 3 |
years age | 3 |
islamic year | 3 |
family members | 3 |
genome sequences | 3 |
sequence analysis | 3 |
serving pilgrims | 3 |
patient received | 3 |
return home | 3 |
local transmission | 3 |
named severe | 3 |
statistical difference | 3 |
circulating strains | 3 |
novel virus | 3 |
coronavirus hku | 3 |
coronavirus resource | 3 |
deaths among | 3 |
hereafter referred | 3 |
seven days | 3 |
total burden | 3 |
clinical severity | 3 |
immune globulin | 3 |
twenty years | 3 |
see supplement | 3 |
three years | 3 |
also observed | 3 |
health systems | 3 |
comparative therapeutic | 3 |
times daily | 3 |
areas using | 3 |
crowd control | 3 |
sensitive tb | 3 |
suspected covid | 3 |
case numbers | 3 |
older age | 3 |
among egyptian | 3 |
strong evidence | 3 |
logistically feasible | 2 |
north africa | 2 |
imported cotton | 2 |
north carolina | 2 |
overseas travel | 2 |
pandemic preparedness | 2 |
sars cases | 2 |
circulating influenza | 2 |
annual pilgrimage | 2 |
live virus | 2 |
combined flowcharts | 2 |
international arrival | 2 |
entry depends | 2 |
mici score | 2 |
prevent another | 2 |
aged years | 2 |
previously described | 2 |
also significantly | 2 |
unknown etiology | 2 |
effectiveness among | 2 |
inhibitory activity | 2 |
inevitable overcrowding | 2 |
provide insights | 2 |
areas may | 2 |
hcq combined | 2 |
specific therapeutic | 2 |
new virus | 2 |
via recombination | 2 |
four patients | 2 |
density estimate | 2 |
rna genome | 2 |
alveolar injury | 2 |
experimental evidence | 2 |
exposure antibody | 2 |
psychological impact | 2 |
small subset | 2 |
therapeutic options | 2 |
april nd | 2 |
constantly updated | 2 |
outbreak caused | 2 |
chest radiographs | 2 |
geosentinel network | 2 |
emergency departments | 2 |
widely across | 2 |
rapidly via | 2 |
arab emirates | 2 |
probably overestimated | 2 |
blocking rna | 2 |
first global | 2 |
system injuries | 2 |
civil aviation | 2 |
viruses tested | 2 |
quarantine system | 2 |
studies evaluating | 2 |
apgar score | 2 |
iranian general | 2 |
inflammatory mediators | 2 |
scheduled flight | 2 |
doctor becomes | 2 |
meningococcal disease | 2 |
special control | 2 |
epidemiological investigation | 2 |
potential covid | 2 |
issued guidelines | 2 |
income countries | 2 |
microbiological effect | 2 |
also provide | 2 |
zoonotic diseases | 2 |
successful cases | 2 |
parameters mirroring | 2 |
health organisation | 2 |
human health | 2 |
escalate globally | 2 |
malaria infections | 2 |
like illnesses | 2 |
three consecutive | 2 |
host evolution | 2 |
tb case | 2 |
chloroquine treatment | 2 |
year per | 2 |
among pakistani | 2 |
growing chain | 2 |
determine whether | 2 |
hwdd nq | 2 |
watery stools | 2 |
increased mortality | 2 |
enters target | 2 |
entry intervention | 2 |
clinical recognition | 2 |
slightly increased | 2 |
direct contact | 2 |
rhesus monkey | 2 |
analysis date | 2 |
different respiratory | 2 |
large tertiary | 2 |
religious rites | 2 |
chinese journal | 2 |
unit beds | 2 |
stark differences | 2 |
infections reported | 2 |
bilateral pleural | 2 |
reported imported | 2 |
blood mononuclear | 2 |
annual trends | 2 |
individuals may | 2 |
possible travelling | 2 |
favorite rock | 2 |
acquiring covid | 2 |
prevent illness | 2 |
next hajj | 2 |
upe gene | 2 |
companion animal | 2 |
including egypt | 2 |
months leading | 2 |
excess alcohol | 2 |
drug use | 2 |
less effective | 2 |
payment coverage | 2 |
initiate another | 2 |
microbiological data | 2 |
may vary | 2 |
also consistent | 2 |
east asia | 2 |
preventing influenza | 2 |
annual growth | 2 |
nine pregnant | 2 |
antiviral treatment | 2 |
west african | 2 |
local health | 2 |
national infection | 2 |
significantly high | 2 |
past fourteen | 2 |
test effectiveness | 2 |
vascular disease | 2 |
received hydroxychloroquine | 2 |
antiviral agents | 2 |
recent advances | 2 |
ph ni | 2 |
matched control | 2 |
adverse drug | 2 |
travel warnings | 2 |
general appearance | 2 |
vero cells | 2 |
initial stages | 2 |
risk category | 2 |
knowledge regarding | 2 |
insufficient hospital | 2 |
health international | 2 |
related illnesses | 2 |
pandemic threats | 2 |
past advisory | 2 |
paguma larvata | 2 |
lung virus | 2 |
cases occurred | 2 |
eventually quarantine | 2 |
strong immune | 2 |
postulates fulfilled | 2 |
virus epidemic | 2 |
undergo mutations | 2 |
hosting communities | 2 |
china severe | 2 |
sialic acid | 2 |
dwelling adults | 2 |
pneumoniae carriage | 2 |
dwelling older | 2 |
travel clinics | 2 |
overall rates | 2 |
high speed | 2 |
population plays | 2 |
economic crisis | 2 |
liver function | 2 |
million teams | 2 |
significant increase | 2 |
rate per | 2 |
premature delivery | 2 |
remdesivir added | 2 |
years based | 2 |
laboratory investigations | 2 |
airport entry | 2 |
distancing may | 2 |
haemorrhagic fever | 2 |
aviation network | 2 |
clinical manifestation | 2 |
pilgrims almost | 2 |
counter sars | 2 |
risch acknowledges | 2 |
four percent | 2 |
patient advocacy | 2 |
similar pattern | 2 |
local situation | 2 |
treatment chloroquine | 2 |
completing hajj | 2 |
temperature measurements | 2 |
another patient | 2 |
less severe | 2 |
enhance treatment | 2 |
acute infection | 2 |
held every | 2 |
ongoing trials | 2 |
within weeks | 2 |
oc infection | 2 |
religious events | 2 |
accommodation facilities | 2 |
studies reporting | 2 |
common colds | 2 |
wore masks | 2 |
survivors compared | 2 |
just like | 2 |
bat coronaviruses | 2 |
disease incidence | 2 |
infections occurring | 2 |
narrative review | 2 |
consensus document | 2 |
majority world | 2 |
zhonghua jie | 2 |
two distinct | 2 |
conflict libyan | 2 |
work adds | 2 |
safety issues | 2 |
laboratory measures | 2 |
using one | 2 |
cases amongst | 2 |
cytokines release | 2 |
southern china | 2 |
large randomized | 2 |
english videos | 2 |
novel disease | 2 |
within years | 2 |
proportion presented | 2 |
airway epithelial | 2 |
surface stability | 2 |
significantly increased | 2 |
flu caused | 2 |
high cytotoxicity | 2 |
advisory consulting | 2 |
beta coronavirus | 2 |
national epidemiological | 2 |
epidemic respiratory | 2 |
libyan armed | 2 |
accepted march | 2 |
will take | 2 |
also similar | 2 |
risk outpatient | 2 |
among us | 2 |
every seven | 2 |
resistance gene | 2 |
provided information | 2 |
epidemic curve | 2 |
like coronaviruses | 2 |
coronavirus causing | 2 |
description hospital | 2 |
news agency | 2 |
tropical diseases | 2 |
sensitive pulmonary | 2 |
per contact | 2 |
processing facilities | 2 |
exclusion criterion | 2 |
youtube useful | 2 |
day prior | 2 |
king fahad | 2 |
may affect | 2 |
good clinical | 2 |
scientific literature | 2 |
aviation point | 2 |
higher percent | 2 |
stampedes occurred | 2 |
results obtained | 2 |
molecular epidemiology | 2 |
patient contacts | 2 |
coronavirus study | 2 |
tropical africa | 2 |
th lymphocytes | 2 |
inhibition test | 2 |
positivity rate | 2 |
adults may | 2 |
radiological pneumonia | 2 |
identifying asymptomatic | 2 |
cough affected | 2 |
inevitable hajj | 2 |
resistant virus | 2 |
among covid | 2 |
surge capacity | 2 |
made available | 2 |
significantly different | 2 |
treat patients | 2 |
hajj respiratory | 2 |
unknown origin | 2 |
beneficial effects | 2 |
high dose | 2 |
also affect | 2 |
danish travelers | 2 |
full coverage | 2 |
different locations | 2 |
growing literature | 2 |
spss inc | 2 |
tmaid dear | 2 |
short time | 2 |
illicit drugs | 2 |
hu xi | 2 |
univariate logistic | 2 |
provide basic | 2 |
cov nasal | 2 |
malaria drug | 2 |
antiviral drug | 2 |
first sars | 2 |
graduated map | 2 |
transmissible diseases | 2 |
health implications | 2 |
unpopular decisions | 2 |
network patterns | 2 |
became infected | 2 |
reporting diseases | 2 |
presentation delay | 2 |
upper tract | 2 |
pacific region | 2 |
novel viral | 2 |
cell activation | 2 |
president tsai | 2 |
multiplex real | 2 |
overall score | 2 |
origins propagated | 2 |
one agent | 2 |
wuhan outbreak | 2 |
korea middle | 2 |
nucleotide analogues | 2 |
north india | 2 |
season influenza | 2 |
samples obtained | 2 |
disabilities within | 2 |
second day | 2 |
individuals independently | 2 |
geographic locations | 2 |
preventive medicine | 2 |
odds ratio | 2 |
true burden | 2 |
van thuan | 2 |
receptors expressed | 2 |
drug chloroquine | 2 |
showed severe | 2 |
saharan countries | 2 |
home till | 2 |
saudi authorities | 2 |
person suffering | 2 |
mokhtari azad | 2 |
severe symptoms | 2 |
pneumococcal vaccines | 2 |
mcg kg | 2 |
treat pulmonary | 2 |
different animal | 2 |
best studied | 2 |
secondary attack | 2 |
current knowledge | 2 |
symptoms include | 2 |
mathematical modeling | 2 |
singapore general | 2 |
occupational exposure | 2 |
overall positivity | 2 |
become symptomatic | 2 |
risk group | 2 |
drug resistant | 2 |
also points | 2 |
disease covid | 2 |
south east | 2 |
chronic kidney | 2 |
treatment efficacy | 2 |
track covid | 2 |
required mechanical | 2 |
ct findings | 2 |
enhanced surveillance | 2 |
develop effective | 2 |
arterial hypertension | 2 |
spreading via | 2 |
predominantly male | 2 |
command center | 2 |
using hand | 2 |
mucosal secretions | 2 |
infection due | 2 |
powerful similarities | 2 |
required hospitalization | 2 |
rather comparable | 2 |
aerosol transmission | 2 |
reported high | 2 |
rna replication | 2 |
outbreak may | 2 |
makkah region | 2 |
zoonotic pathogens | 2 |
travelling conditions | 2 |
antiviral efficacy | 2 |
additional papers | 2 |
risk behaviors | 2 |
cases including | 2 |
reverse transcription | 2 |
stage may | 2 |
outbreak resulted | 2 |
transfer across | 2 |
respective world | 2 |
immune system | 2 |
fifth day | 2 |
scale raster | 2 |
bacteria among | 2 |
regarding potential | 2 |
largest cities | 2 |
also apply | 2 |
low toxicity | 2 |
urgent prevention | 2 |
defining influenza | 2 |
leggat also | 2 |
vitro results | 2 |
chief focus | 2 |
requiring hospitalization | 2 |
three basic | 2 |
advocacy groups | 2 |
will cause | 2 |
index cases | 2 |
spontaneous gatherings | 2 |
susceptible person | 2 |
higher prevalence | 2 |
human cells | 2 |
repeatedly tested | 2 |
steroid use | 2 |
poultry processing | 2 |
may pose | 2 |
receptor recognition | 2 |
local residents | 2 |
consecutive years | 2 |
symptoms among | 2 |
workers serving | 2 |
also admirable | 2 |
palm civets | 2 |
federal health | 2 |
median wbcs | 2 |
nominal monthly | 2 |
epidemiologic features | 2 |
common influenza | 2 |
performed just | 2 |
medical diseases | 2 |
resource center | 2 |
conventional drug | 2 |
subjectively healthy | 2 |
surrounding holy | 2 |
april st | 2 |
population model | 2 |
high fever | 2 |
xxxx key | 2 |
medicine clinics | 2 |
infection will | 2 |
cardiovascular conditions | 2 |
will make | 2 |
polysaccharide pneumococcal | 2 |
examines clinical | 2 |
medical supplies | 2 |
gene test | 2 |
past decade | 2 |
associated sore | 2 |
associated mers | 2 |
will enhance | 2 |
spoken language | 2 |
reference category | 2 |
papers published | 2 |
valent conjugate | 2 |
events will | 2 |
capital city | 2 |
till now | 2 |
patient recovers | 2 |
proinflammatory cytokine | 2 |
million residents | 2 |
pathogenic viruses | 2 |
seems reasonable | 2 |
current circumstances | 2 |
prevention efforts | 2 |
red dot | 2 |
previous disease | 2 |
recorded limited | 2 |
five million | 2 |
pilot study | 2 |
several days | 2 |
proteus mirabilis | 2 |
care structures | 2 |
person becomes | 2 |
normal white | 2 |
species variation | 2 |
even today | 2 |
analysis center | 2 |
planned travel | 2 |
rock group | 2 |
exposed population | 2 |
direct flights | 2 |
useful source | 2 |
medicine focuses | 2 |
using non | 2 |
good quality | 2 |
replicate nucleic | 2 |
oo wc | 2 |
known assumptions | 2 |
religious places | 2 |
various authorities | 2 |
awaited mass | 2 |
gamma distribution | 2 |
including japan | 2 |
syndrome caused | 2 |
attending pilgrims | 2 |
based information | 2 |
influenza negative | 2 |
dependent rna | 2 |
high morbidity | 2 |
city pair | 2 |
will end | 2 |
small numbers | 2 |
severe sepsis | 2 |
cov middle | 2 |
cases among | 2 |
plasmodium vivax | 2 |
lymphocyte count | 2 |
patients ranged | 2 |
reports regarding | 2 |
clinical disease | 2 |
history abroad | 2 |
detected influenza | 2 |
uuo oeyc | 2 |
surveillance network | 2 |
latest novel | 2 |
assuming one | 2 |
african ebola | 2 |
spread simulation | 2 |
selected mina | 2 |
quickly spread | 2 |
consistent guideline | 2 |
second week | 2 |
similar magnitudes | 2 |
recent ph | 2 |
lower lymphocyte | 2 |
acute cardiac | 2 |
future either | 2 |
must also | 2 |
newborn mice | 2 |
skewed distributions | 2 |
clinical information | 2 |
affected global | 2 |
pharmacological actions | 2 |
rapidly spreading | 2 |
ni observations | 2 |
symptomatic uk | 2 |
causes including | 2 |
resistant pathogens | 2 |
may include | 2 |
malaria free | 2 |
rates ranging | 2 |
significant impact | 2 |
made using | 2 |
timely investigation | 2 |
gastrointestinal tract | 2 |
probable zoonotic | 2 |
swab samples | 2 |
admission intervals | 2 |
fourteen centuries | 2 |
international payment | 2 |
last decade | 2 |
lower respiratory | 2 |
influenza center | 2 |
considered novel | 2 |
olaniyi ayobami | 2 |
appropriate preventive | 2 |
comparative analysis | 2 |
early outbreak | 2 |
extracted using | 2 |
data regarding | 2 |
gua abq | 2 |
therapeutics drugs | 2 |
jackson foundation | 2 |
missed opportunities | 2 |
international borders | 2 |
effective treatment | 2 |
simulated characteristics | 2 |
epidemic areas | 2 |
received chloroquine | 2 |
sewer waters | 2 |
human covs | 2 |
antiretroviral therapy | 2 |
tokyo olympic | 2 |
person spread | 2 |
screening approaches | 2 |
dna rna | 2 |
calculated using | 2 |
cumulative cases | 2 |
increasing endosomal | 2 |
new data | 2 |
sars infected | 2 |
covs including | 2 |
contained increases | 2 |
two major | 2 |
study date | 2 |
empirical treatment | 2 |
coexisting chronic | 2 |
modeling framework | 2 |
subtype asia | 2 |
widespread testing | 2 |
transcriptase polymerase | 2 |
probable transmission | 2 |
increasing number | 2 |
chest radiography | 2 |
better understand | 2 |
global market | 2 |
two monoclonal | 2 |
highly effective | 2 |
uzoma abakporo | 2 |
sport played | 2 |
virus circulation | 2 |
differentiating covid | 2 |
transmission rates | 2 |
medical attention | 2 |
strains isolated | 2 |
asymptomatic carrier | 2 |
allow treating | 2 |
pandemic response | 2 |
reported olfactory | 2 |
sas institute | 2 |
gi symptoms | 2 |
reproductive number | 2 |
views day | 2 |
oxygen therapy | 2 |
small molecule | 2 |
supportive treatment | 2 |
videos uploaded | 2 |
identification moderates | 2 |
white blood | 2 |
proven protease | 2 |
essential medicines | 2 |
across china | 2 |
one parameter | 2 |
unstable rna | 2 |
study results | 2 |
australian pilgrims | 2 |
research center | 2 |
travel encounter | 2 |
amino acids | 2 |
vibrio cholerae | 2 |
highly pathogenic | 2 |
important source | 2 |
modern humanity | 2 |
among uk | 2 |
particle lysin | 2 |
healthcare services | 2 |
use established | 2 |
research outcomes | 2 |
temperature cut | 2 |
various scenarios | 2 |
cell membranes | 2 |
predict potential | 2 |
undiagnosed active | 2 |
tomography findings | 2 |
located within | 2 |
health concern | 2 |
community mitigation | 2 |
sars cov | 2 |
tat protein | 2 |
class ii | 2 |
long engaged | 2 |
coming months | 2 |
lancet infect | 2 |
spread via | 2 |
likely due | 2 |
two authors | 2 |
obtained using | 2 |
coagulation parameters | 2 |
assess compliance | 2 |
young adult | 2 |
disease entry | 2 |
health regulations | 2 |
future sars | 2 |
one day | 2 |
showed leukopenia | 2 |
liverpool fans | 2 |
cell fusion | 2 |
transcription polymerase | 2 |
health emergencies | 2 |
epidemiological surveillance | 2 |
clinical case | 2 |
diagnostic testing | 2 |
search results | 2 |
frequent occurrence | 2 |
recovered state | 2 |
events attended | 2 |
pregnancy outcomes | 2 |
serious adverse | 2 |
provincial health | 2 |
asymptomatic coronavirus | 2 |
th jan | 2 |
system including | 2 |
patient returning | 2 |
new ventricular | 2 |
tract symptoms | 2 |
early identification | 2 |
year pattern | 2 |
recall attending | 2 |
saudi tb | 2 |
animal hosts | 2 |
square kilometer | 2 |
hospital network | 2 |
luz alba | 2 |
testing centers | 2 |
pneumonia patients | 2 |
health responders | 2 |
therapeutic agents | 2 |
fully understood | 2 |
limited malarial | 2 |
sixth day | 2 |
participants gave | 2 |
reliable source | 2 |
sars alert | 2 |
sindbis virus | 2 |
inanimate surfaces | 2 |
chloroquine phosphate | 2 |
first reported | 2 |
initial outbreak | 2 |
pandemic virus | 2 |
lancet covid | 2 |
day follow | 2 |
exposed individuals | 2 |
returning traveler | 2 |
many limitations | 2 |
decreased significantly | 2 |
coding region | 2 |
key points | 2 |
ebola epidemic | 2 |
sectional survey | 2 |
impact will | 2 |
overall prevalence | 2 |
swine acute | 2 |
enzyme coding | 2 |
cases hydroxychloroquine | 2 |
medicine practitioners | 2 |
daily life | 2 |
heart failure | 2 |
high case | 2 |
digestive system | 2 |
spectrum filovirus | 2 |
systolic pressure | 2 |
disease patients | 2 |
carrier transmission | 2 |
basic reproductive | 2 |
city ethics | 2 |
patients also | 2 |
supplementary table | 2 |
available weapons | 2 |
tract respiratory | 2 |
disease will | 2 |
cells via | 2 |
four days | 2 |
baseline characteristics | 2 |
reported covid | 2 |
governments across | 2 |